Postmarketing migraine survey of frovatriptan: Effectiveness and tolerability vs previous triptans, NSAIDs or a combination

Current Medical Research and Opinion

Volumn 25, Issue 11, 2009, Pages 2711-2721

  Cady, Roger K ^a   Banks III, James ^b   Jones, Beverly A ^c   Campbell, John ^c  

^a HEADACHE CARE CENTER   (United States)

^b Mercy Health Research   (United States)

^c ENDO PHARMACEUTICALS INC   (United States)

Author keywords

Headache disorders; Migraine; Migraine treatment; Postmarketing drug surveillance; Triptans

Indexed keywords

ANALGESIC AGENT; FROVATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; TRIPTAN DERIVATIVE;

ADULT; ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE;

ADULT; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARBAZOLES; DATA COLLECTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PATIENT SATISFACTION; PRODUCT SURVEILLANCE, POSTMARKETING; TABLETS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 72549111492     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903285449     Document Type: Article

References (41)

1. Harpole LH, Samsa GP, Matchar DB, et al. Burden of illness and satisfaction with care among patients with headache seen in a primary care setting. Headache 2005;45:1048-1055
2. Malik SN, Hopkins M, Young WB, et al. Acute migraine treatment: patterns of use and satisfaction in a clinical population. Headache 2006;46:773-780
3. Mathew NT, Kailasam J, Gentry P, et al. Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial. Headache 2000;40:464-465 (Pubitemid 30421878)
4. Powers C, Szeto S, Pangtay D et al. Evaluation of migraineurs' preferences for naratriptan over conventional first-line agents. Arch Fam Med 2000;9:753-758 (Pubitemid 30640851)
5. Cady R, Martin V, Mauskop A et al. Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache 2006;46:914-924 (Pubitemid 43794743)
6. Cady R, Elkind A, Goldstein J, et al. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Med Res Opin 2004;20:1465-1472 (Pubitemid 39361351)
7. Mathew NT. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache 2003;43:1075-1079
8. Mathew NT, Kailasam J, Meadors L. Early treatment of migraine with rizatriptan: a placebo-controlled study. Headache 2004;44:669-673 (Pubitemid 38931897)
9. Landy S, Savani N, Shackelford S et al. Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine. Int J Clin Pract 2004;58:913-919 (Pubitemid 39642611)
10. Silberstein S. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee for the American Academy of Neurology. Neurology 2000;55:754-762 (Pubitemid 30727712)
11. Geraud G, Lanteri-Minet M, Lucas C, et al. French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther 2004;26:1305-1318 (Pubitemid 39445352)
12. Smith TR, Banks JW, Nicholson RA. 'Is a triptan the first medication you take?': how order of use differentiates migraine sufferers' triptan adherence and quality of life. Headache 2007;47:755
13. Garcia-Ramos G, MacGregor EA, Hilliard B et al. Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine. Cephalalgia 2003;23:869-876 (Pubitemid 37352623)
14. Allais G, Acuto G, Cabarrocas X et al. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol Sci 2006;27:S193-7 (Pubitemid 44390141)
15. Nett R, Landy S, Shackelford S et al. Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol 2003;102:835-842 (Pubitemid 37206421)
16. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-1675
17. Dahlof CG. Infrequent or non-response to oral sumatriptan does not predict response to other triptans - review of four trials. Cephalalgia 2006;26:98-106
18. Diener HC, Gendolla A, Gebert I, et al. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Headache 2005;45:874-882 (Pubitemid 41045364)
19. Farkkila M, Olesen J, Dahlof C et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 2003;23:463-471 (Pubitemid 36776063)
20. Krymchantowski AV. Acute treatment of migraine. Breaking the paradigm of monotherapy. BMC Neurol 2004;4:4
21. Krymchantowski AV, Bigal ME. Polytherapy in the preventive and acute treatment of migraine: fundamentals for changing the approach. Expert Rev Neurother 2006;6:283-289
22. Krymchantowski AV, Adriano M, Fernandes D. Tolfenamic acid decreases migraine recurrence when used with sumatriptan. Cephalalgia 1999;19:186-187 (Pubitemid 29202151)
23. Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr 2000;58:428-430
24. Loder E. Fixed drug combinations for the acute treatment of migraine: place in therapy. CNS Drugs 2005;19:769-784 (Pubitemid 41324064)
25. Brandes JL, Kudrow D, Stark SR et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA 2007;297:1443-1454 (Pubitemid 46556470)
26. Pfaffenrath V, Spierings EL. [Treatment of acute migraine attacks: effective and economic alternative.] Nervenheilkunde 2004;23:545-548
27. Diener HC, Gendolla A. Part IV: effects of zolmitriptan orally disintegrating tablet on migraine symptoms and ability to perform normal activities: a postmarketing surveillance study in Germany. Curr Med Res Opin 2005;21(Suppl. 3):S18-24 (Pubitemid 41152959)
28. Zimmermann T, Dietrich H, Wisser KH, et al. The efficacy and tolerability of Valette: a postmarketing surveillance study. Eur J Contracept Reprod Health Care 1999;4:155-164
29. Hajak G, Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases. Int Clin Psychopharmacol 1998;13:157-167 (Pubitemid 28372339)
30. Bigal M, Rapoport A, Aurora S et al. Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache 2007;47:475-479 (Pubitemid 46625257)
31. Ryan R, Geraud G, Goldstein J et al. Clinical efficacy of frovatriptan: placebo-controlled studies. Headache 2002;42(Suppl. 2):S84-92 (Pubitemid 34568921)
32. Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003;43:376-388 (Pubitemid 36417768)
33. Chia YC, Lim SH, Wang SJ et al. Efficacy of eletriptan in migraineurs with persistent poor response to nonsteroidal anti-inflammatory drugs. Headache 2003;43:984-990
34. Stronks DL, Tulen JH, Bussmann HB et al. Effects of naratriptan versus naproxen on daily functioning in the acute treatment of migraine: a randomized, double-blind, double-dummy, crossover study. Headache 2003;43:845-852
35. Eich E, Reeves JL, Jaeger B, et al. Memory for pain: relation between past and present pain intensity. Pain 1985;23:375-380 (Pubitemid 16212850)
36. van den Brink M, Bandell-Hoekstra EN, Abu-Saad HH. The occurrence of recall bias in pediatric headache: a comparison of questionnaire and diary data. Headache 2001;41:11-20
37. Stark S, Spierings EL, McNeal S et al. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 2000;40:513-520 (Pubitemid 30497409)
38. Tobin J, Shaw R, Pawsey S et al. Characteristics of patients with inadequate responses to acute triptan treatment for menstrual migraine. Headache 2007;47:786
39. Jhee SS, Shiovitz T, Crawford AW, et al. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet 2001;40:189-205 (Pubitemid 32324450)
40. Frova® tablets (frovatriptan succinate). Full Prescribing Information, Endo Pharmaceuticals Inc., Chadds Ford, PA, 2007
41. Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Headache 2002;42(Suppl. 2):S93-9 (Pubitemid 34568922)